Q-omics provides the consensus-scored PRRX1 profile across patient tissues and cancer cell-line models. PRRX1 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, PRRX1 is differentially expressed in 12, with the highest sampling consensus in COAD. Additionally, PRRX1 protein abundance shows 32,987 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight KIRP, COAD, and LUAD as cancer lineages where PRRX1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PRRX1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PRRX1 survival associations across molecular data types. PRRX1 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (8) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PRRX1 RNA expression–survival associations across cancer types. High PRRX1 expression shows unfavorable associations in KIRP, UVM, BLCA and STAD, but favorable associations in HNSC and LAML. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for PRRX1 RNA expression.
This table summarizes PRRX1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 6. The strongest signals are observed in COAD for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for PRRX1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PRRX1 shows lower tumor expression in THCA and higher tumor expression in COAD, LUAD, LIHC, HNSC and STAD. The COAD box plot shows higher PRRX1 RNA expression in tumor versus normal tissue (log2 FC = +1.790, t-test p < 0.001).
This table shows molecular features associated with PRRX1 in patient tissues and cancer cell lines. In patient samples, PRRX1 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, PRRX1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and SKIN.
